Skip to Content

Nascent Biotech Inc NBIO

Rating as of

Morningstar’s Analysis

Valuation
Currency in USD
Is it the right time to buy or sell?
Find out with Morningstar Premium
Is it the right time to buy or sell?
Find out with Morningstar Premium

1-Star Price

PREMIUM

5-Star Price

PREMIUM

Economic Moat

PREMIUM

About Quantitative Ratings

Morningstar Quantitative ratings for equities (denoted on this page by) are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies withratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating. Click here for more on how to use these ratings.

Company Profile

Business Description

Nascent Biotech Inc is a United States-based clinical-stage biopharmaceutical company. It is focused on the development and delivery of human antibodies and cytokine responses to the treatment of cancer. The company's products include Pritumumab, CLNH5, and MultiPharm. It is actively engaged in the development of Pritumumab which would be used for the treatment of brain cancer and pancreatic cancer. They are also exploring the use of Pritumumab against other viruses.

Contact
6330 Nancy Ridge Drive, Suite 105
San Diego, CA, 92121
T +1 612 961-5656
Sector Healthcare
Industry Biotechnology
Most Recent Earnings Mar 31, 2020
Fiscal Year End Mar 31, 2021
Stock Type Slow Growth
Employees